RT Journal Article
SR Electronic
T1 Hydroxychloroquine in the Pregnancies of Women with Lupus: A Meta-Analysis of Individual Participant Data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.21.21267285
DO 10.1101/2021.12.21.21267285
A1 Clowse, Megan E. B.
A1 Eudy, Amanda M.
A1 Balevic, Stephen
A1 Sanders-Schmidler, Gillian
A1 Kosinski, Andrzej
A1 Fischer-Betz, Rebecca
A1 Gladman, Dafna
A1 Molad, Yair
A1 Nalli, Cecilia
A1 Mokbel, Abir
A1 Tincani, Angela
A1 Urowitz, Murray
A1 Bay, Caroline
A1 van Noord, Megan
A1 Petri, Michelle
YR 2021
UL http://medrxiv.org/content/early/2021/12/21/2021.12.21.21267285.abstract
AB Objective Multiple guidelines recommend continuing hydroxychloroquine (HCQ) for systemic lupus erythematosus (lupus) during pregnancy based on observational data. The goal of this individual patient data meta-analysis was to combine multiple datasets to compare pregnancy outcomes in women with lupus on and off HCQ.Methods Eligible studies included prospectively-collected pregnancies in women with lupus. After a manuscript search, 7 datasets were obtained. Pregnancy outcomes and lupus activity were compared for pregnancies with a visit in the first trimester in women who did or did not take HCQ throughout pregnancy. Birth defects were not systematically collected. This analysis was conducted in each dataset and results were aggregated to provide a pooled odds ratio.Results Seven cohorts provided 938 pregnancies in 804 women. After selecting one pregnancy per patient with a 1st trimester visit, 668 pregnancies were included; 63% took HCQ throughout pregnancy. Compared to pregnancies without HCQ, those with HCQ had lower rates of highly active lupus, but did not have different rates of fetal loss, preterm birth, or preeclampsia. Among women with low lupus activity, HCQ reduced the risk for preterm delivery.Conclusion This large study of prospectively-collected lupus pregnancies demonstrates a decrease in SLE activity among woman who continue HCQ through pregnancy and no harm to pregnancy outcomes. Like all studies of HCQ in lupus pregnancy, this study is confounded by indication and non-adherence. As this study confirms the safety of HCQ and diminished SLE activity with use, it is consistent with current recommendations to continue HCQ throughout pregnancy.Competing Interest StatementClowse: Funding: AHRQ 1K18HS023443-01A1, Arthritis Foundation; Grants: GSK; Consulting and Advisory Board: UCB. Eudy: Grant funding: NIH NCATS Award 1KL2TR002554. Balevic: Grants: NIH, US FDA, PCORI, RRF, CARRA; Consulting: UCB; Travel: FDA; Leadership: CARRA Assistant Scientific Director. Gladman: Grants and or consulting fees from AstraZeneca; Leadership: Member of the Systemic Lupus International Collaborating Clinics group; served on the Medical advisory board of the Lupus foundation of America. Petri: Grant NIH RO-1 AR069572. The other authors report no significant competing interests or grant funding that pertains to the research within this manuscript.Funding StatementClowse: AHRQ 1K18HS023443-01A1; Arthritis Foundation, Arthritis Investigator Award. Eudy: NIH NCATS Award Number 1KL2TR002554 Petri: NIH RO-1 AR069572Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Each dataset was collected under a local IRB protocol and patients provided informed consent prior to participation. The meta-analysis was approved by Duke University IRB; protocol number Pro00066961.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.